He has been working with the program in the clinical setting since 1992. Additional research efforts have focused on the social implications of vaccine trial participation, the study of mucosal antibody in HIV and community advocacy in HIV vaccine trials. He is also the representative on the Vaccine-Induced Seropositivity taskforce.